[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337948-105":59,"doc-detail-337948-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","microbiome-and-pancreatic-cancer-time-to-think-about-chemotherapy","Microbiome and pancreatic cancer: time to think about chemotherapy","","Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer marked by late diagnosis, rapid progression, and high mortality. Its dense stromal tumor environment and immunosuppressive milieu drive resistance to standard chemotherapy and radiation. This comprehensive review explains how the microbiome modulates chemotherapy efficacy and outcomes in PDAC, including effects on drug metabolism, resistance, and immune interactions, and reviews advanced tools such as AI, low-biomass analysis, and patient-derived organoids to identify mechanisms and gaps for personalized therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/microbiome-and-pancreatic-cancer-time-to-think-about-chemotherapy/337948/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/microbiome-and-pancreatic-cancer-time-to-think-about-chemotherapy/337948.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does PDAC often resist standard chemotherapy and radiation?","Question",{"text":112,"@type":113},"PDAC features a dense stromal tumor environment with an immunosuppressive milieu, which contributes to resistance against standard therapies such as chemotherapy and radiation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can the microbiome influence chemotherapy efficacy in PDAC?",{"text":117,"@type":113},"The microbiome can affect drug bioavailability and metabolism through microbial metabolites, and intracellular microbial elements may also alter tumor signaling, immune evasion, and drug resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What future approaches does the review highlight for studying microbe–cancer interactions?",{"text":121,"@type":113},"It discusses cutting-edge methodologies including artificial intelligence, low-biomass microbiome analysis, and patient-derived organoid models to clarify nuanced interactions and inform personalized interventions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337948,1790096428,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","GUT MICROBES  \n2024, VOL. 16, NO. 1, 2374596 [https://doi.org/10.1080/19490976.2024.2374596](https://doi.org/10.1080/19490976.2024.2374596)  \nREVIEW  \nMicrobiome and pancreatic cancer: time to think about chemotherapy  \nJuliana de Castilhosa,b, Katharina Tillmannsa,b, Jana Blessinga,b, Arnelyn Larañoa,b, Vadim Borisova,b, and Christoph K. Stein-Thoeringera,b  \naTranslational Microbiome Research, Internal Medicine I and M3 Research Center, University Hospital Tuebingen, Tübingen, Germany; bCluster of Excellence “Controlling Microbes to Fight Infections”(CMFI), University of Tuebingen, Tübingen, Germany  \nABSTRACT  \nPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by late diagnosis, rapid progression, and a high mortality rate. Its complex biology, characterized by a dense, stromal tumor environment with an immunosuppressive milieu, contributes to resistance against standard treatments like chemotherapy and radiation. This comprehensive review explores the dynamic role of the microbiome in modulating chemotherapy efficacy and outcomes in PDAC. It delves into the microbiome’s impact on drug metabolism and resistance, and the interaction between microbial elements, drugs, and human biology. We also highlight the significance of specific bacterial species and microbial enzymes in influencing drug action and the immune response in the tumor microenvironment. Cutting-edge methodologies, including artificial intelligence, low-biomass microbiome analysis and patient-derived organoid models, are discussed, offering insights into the nuanced interactions between microbes and cancer cells. The potential of microbiome-based interventions as adjuncts to conventional PDAC treatments are discussed, paving the way for personalized therapy approaches. This review synthesizes recent research to provide an in-depth understanding of how the microbiome affects chemotherapy efficacy. It focuses on elucidating key mechanisms and identifying existing knowledge gaps. Addressing these gaps is crucial for enhancing personalized medicine and refining cancer treatment strategies, ultimately improving patient outcomes.  \nARTICLE HISTORY  \nReceived 24 January 2024 Revised 26 May 2024 Accepted 26 June 2024  \nKEYWORDS  \nPancreatic Ductal Adenocarcinoma (PDAC); microbiome; chemotherapy efficacy; microbial metabolism; tumor microenvironment  \n1. Introduction  \nThe human microbiome, an intricate and diverse ecosystem distributed throughout various body sites, plays a pivotal role in orchestrating essential functions that affect both health and disease states. 1–4 In recent years, emerging evidence underscores the critical role of the microbiome in carcinogenesis, showing that it is not only implicated in tumor development and progression, but also serves as a potential biomarker for early detection or for progression and treatment resistance in several types of cancer.5–7 Additionally, mounting evidence suggests that the microbiome has been shown to modulate the efficacy and toxicity of cancer immuno- and chemotherapies.8–13 Being aware of the dynamic interplay between the human microbiome in different types of cancer, it becomes necessary to uncover the specific microbiome interactions and mechanisms to eventually  \nimprove treatment efficacy and reduce treatment toxicity. 14, 15  \nPancreatic ductal adenocarcinoma (PDAC) is currently the third most common cause of cancerrelated deaths, and the incidence of this disease has been steadily increasing by approximately 1% each year. 16 Despite significant advances in the treatment of PDAC, like the polychemotherapeutic regimens of FOLFIRINOX (5FU, leucovorin, irinotecan, and oxaliplatin) and the combination of gemcitabine and a nanoparticle albumin-bound paclitaxel (nab-paclitaxel), which have been reported to significantly improve overall survival, patients still have a poor prognosis with 5-year survival rates of 10% in the metastatic setting. 17–19 This can be attributed to vario","cbCaipNjb2vF3Anv","https://ap.wps.com/l/cbCaipNjb2vF3Anv","pdf",1386987,33,"English","# Abstract\n# 1. Introduction\n## The microbiome in cancer biology\n## PDAC burden and current treatment limitations\n## Toxicity and the need for biomarkers\n## Gut microbiome and chemotherapy modulation","[{\"question\":\"Why does PDAC often resist standard chemotherapy and radiation?\",\"answer\":\"PDAC features a dense stromal tumor environment with an immunosuppressive milieu, which contributes to resistance against standard therapies such as chemotherapy and radiation.\"},{\"question\":\"How can the microbiome influence chemotherapy efficacy in PDAC?\",\"answer\":\"The microbiome can affect drug bioavailability and metabolism through microbial metabolites, and intracellular microbial elements may also alter tumor signaling, immune evasion, and drug resistance.\"},{\"question\":\"What future approaches does the review highlight for studying microbe–cancer interactions?\",\"answer\":\"It discusses cutting-edge methodologies including artificial intelligence, low-biomass microbiome analysis, and patient-derived organoid models to clarify nuanced interactions and inform personalized interventions.\"}]","Microbiome and pancreatic cancer: time to think about chemotherapy | PDF",1790021309,83]